The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis, MD, University of Athens, Athens, Greece, proposes treatment strategies for patients with light chain (AL) amyloidosis beyond stem cell transplantation (SCT) and chemotherapy, commenting on the role of venetoclax, lenalidomide- and pomalidomide-containing regimens, and other novel agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
